Financing ·
Immix Biopharma prices $125M public offering of common stock at $11 per share
IMMXImmix Biopharma, Inc.
Immix Biopharma, Inc. priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share on September 29, 2026. The transaction is expected to generate gross proceeds of approximately $125 million and net proceeds of roughly $117.1 million after deducting underwriting discounts and estimated offering expenses. J.P. Morgan Securities LLC served as the sole book-running manager for the deal. The offering closed on September 30, 2026, subject to customary conditions. Immix intends to utilize the net proceeds to fund the development of its lead candidate NXC-201, as well as working capital and general corporate purposes. Immix Biopharma is a clinical-stage biotechnology company focused on developing therapies for relapsed or refractory AL Amyloidosis.